Drs Michael Saag and Judith Currier discuss options for long-acting HIV therapies, minimizing patient interactions with the healthcare system, and honoring patient preferences.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/963242). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.
Resources
AIDS Clinical Trials Group (ACTG) https://www.niaid.nih.gov/research/aids-clinical-trials-group
Cabotegravir/Rilpivirine (Rx) https://reference.medscape.com/drug/cabenuva-cabotegravir-rilpivirine-4000156
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563641/
Antiretroviral Therapy for HIV Infection https://emedicine.medscape.com/article/1533218-overview
Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/interactions-between-integrase-inhibitors-and-non-nucleoside
Initiation of Long-acting Cabotegravir Plus Rilpivirine as Direct-to-Injection or With an Oral Lead-in in Adults With HIV-1 Infection: Week 124 Results of the Open-Label Phase 3 FLAIR Study https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(21)00184-3/fulltext
Lenacapavir (Pending FDA Approval) https://reference.medscape.com/drug/lenacapavir-4000240
Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir https://www.gilead.com/news-and-press/company-statements/gilead-and-merck-announce-temporary-pause-in-enrollment-for-phase-2-study-evaluating-an-oral-weekly-combination-regimen-of-investigational-islatravir-and-investigational-lenacapavir
Drug Database: Lenacapavir https://clinicalinfo.hiv.gov/en/drugs/lenacapavir/health-professional
Doravirine Prescribing Information https://www.merck.com/product/usa/pi_circulars/p/pifeltro/pifeltro_pi.pdf
A5357: A Study of Long-Acting Cabotegravir Plus VRC01LS to Maintain Viral Suppression in HIV-1-Infected Adults https://actgnetwork.org/studies/actg-a5357-a-study-of-long-acting-cabotegravir-plus-vrc01ls-to-maintain-viral-suppression-in-hiv-1-infected-adults/
Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV https://clinicaltrials.gov/ct2/show/NCT04334915?term=ACTG+5363&draw=2&rank=1
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189692/
Evusheld (Formerly AZD7442) Long-acting antibody Combination Authorised for Emergency Use in the US for Pre-exposure Prophylaxis (Prevention) of COVID-19 https://www.astrazeneca.com/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-authorised-for-emergency-use-in-the-us-for-pre-exposure-prophylaxis-prevention-of-covid-19.html